EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The state of cancer care in Russia: prostate cancer (С61). Morbidity, mortality, quality of accounting, 1-year lethality. Part 1. (clinical-population study)

Vakhtang M. Merabishvili, Dmitri I. Krivonosov, Maria V. Berkut, Vladimir Y. Startsev, Yulia P. Yurkova, Alexander K. Nosov, Vladimir V. Perelygin

Pharmacy Formulas · 30.04.2026 · 7 (4) · 18-31

DOI: 10.17816/phf698855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy Formulas, online erschienen am 30.04.2026. Verfasst von Vakhtang M. Merabishvili und 6 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study is devoted to a comprehensive analysis of the epidemiological situation related to prostate cancer (PCa) in the Russian Federation and the Northwestern Federal District (NWFD). Today, PCa is the leading cause of oncological morbidity among the male population, ranking first (19.1%) in the structure of malignant neoplasms in Russia as of 2023. In the NWFD and Saint Petersburg, these figures reach 19.74% and 21.49%, respectively. The relevance of the work is driven by a steady increase in incidence rates, including among the working-age population, against the backdrop of global trends. The aim of the study is to examine the patterns in the dynamics of incidence and mortality rates, evaluate the quality of reporting for newly registered PCa cases, calculate one-year lethality using the Population-based Cancer Registry (PCR) database of the NWFD, and explore modern diagnostic capabilities. The study established that despite the rising incidence in the NWFD, there is a observed decline in mortality and one-year lethality. A key indicator of improved reporting quality was the decrease in the Data Reliability Index (DRI) to 0.22–0.23 by 2023. Significant progress in early diagnosis was identified: while Stage IV was predominant (33.7%) among men under 60 in the year 2000, by 2023, the diagnosis was verified at Stage II in 43.1% of patients. Similar positive dynamics were observed in the patient group aged 60 and older. The findings indicate an improvement in the screening system and the increased effectiveness of oncological care in the region, which facilitates timely disease detection and improves patient prognosis. The global context of the study confirms a twofold increase in the absolute number of cases in the Russian Federation over the last decades, necessitating further development of preventive and diagnostic measures.

Zitieren

APA

Merabishvili, V. M., Krivonosov, D. I., Berkut, M. V., Startsev, V. Y., Yurkova, Y. P., Nosov, A. K., & Perelygin, V. V. (2026). The state of cancer care in Russia: prostate cancer (С61). Morbidity, mortality, quality of accounting, 1-year lethality. Part 1. (clinical-population study). Pharmacy Formulas, 7(4), 18-31. https://doi.org/10.17816/phf698855

Vancouver

Merabishvili VM, Krivonosov DI, Berkut MV, Startsev VY, Yurkova YP, Nosov AK, et al. The state of cancer care in Russia: prostate cancer (С61). Morbidity, mortality, quality of accounting, 1-year lethality. Part 1. (clinical-population study). Pharmacy Formulas. 2026;7(4):18-31. doi:10.17816/phf698855

BibTeX
@article{Merabishvili2026,
  author = {Merabishvili, Vakhtang M. and Krivonosov, Dmitri I. and Berkut, Maria V. and Startsev, Vladimir Y. and Yurkova, Yulia P. and Nosov, Alexander K. and Perelygin, Vladimir V.},
  title = {The state of cancer care in Russia: prostate cancer (С61). Morbidity, mortality, quality of accounting, 1-year lethality. Part 1. (clinical-population study)},
  journal = {Pharmacy Formulas},
  year = {2026},
  volume = {7},
  number = {4},
  pages = {18--31},
  doi = {10.17816/phf698855}
}
Kostenlos starten →